leisure time -WSS

leisure time

author：fashion 2025-10-01 00:52:39 - browse：9

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： A new drug could help frostbite victims avoid its ravages

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

FDA warns medical device makers about rise in fabricated data

CommonSpirit Health keeps growing, even as it loses money

A new drug could help frostbite victims avoid its ravages

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Peter Hotez and the public health issue of online harassment

Why are Kaiser Permanente staff considering a strike?

Tori Bowie and the unacceptable rates of Black maternal death

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Psychedelics group wrestles with new pharma identity

How AI helped researchers track recovery from depression

At least 13 dead in Texas as scorching temps continue

Medical student insurance fails on mental health care coverage

Supreme Court strikes down use of affirmative action

FDA warns medical device makers about rise in fabricated data

Wikipedia

Weight loss drugs aren’t covered by Obamacare. That may change

Second xenotransplant done with gene

Hospitals are piloting generative AI tools as regulators play catch

CDC's new outbreak response network to include Northeastern

Opioid cravings were reduced by anti

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Wikipedia

leisure time

knowledge

entertainment